Study of Sacituzumab Govitecan in Patients With Solid Tumor
← catalyst calendarNCT05119907 · readout ≤ 72 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
53actual
Sites
13
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-10-12 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor
Intervention
- Drug: Sacituzumab Govitecan-hziy — also filed as IMMU-132, Trodelvy™, GS-0132
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Investigator Assessment
measured Up to 4 years
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed